文献速递骨质疏松与代谢性骨病

阿巴洛帕肽提高糖皮质激素诱导骨量减少的去卵巢兔的骨密度与骨强度

Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia.
PubMed 文献 · Osteoporos Int · 2019-05-03

研究在去卵巢兔中给予甲泼尼龙6周造成糖皮质激素诱导骨量减少,随后联合阿巴洛帕肽5或25 μg/kg/日治疗12周;25 μg/kg/日组显著逆转椎体和股骨近端骨密度及股骨中段皮质骨和椎体、股骨远端松质骨缺陷,并使股骨中段极限载荷和弯曲刚度恢复至与假手术对照相似。

要点

  • 去卵巢兔接受甲泼尼龙6周后椎体和股骨近端面积骨密度、股骨中段皮质面积、厚度和体积骨密度及椎体与股骨远端松质骨量均显著低于假手术对照。
  • 阿巴洛帕肽25 μg/kg/日治疗12周显著逆转上述骨密度和骨微结构缺陷,并改善松质骨微结构。
  • 阿巴洛帕肽25 μg/kg/日组股骨中段极限载荷和弯曲刚度与假手术对照相似。

核心结论

  • 阿巴洛帕肽25 μg/kg/日可减轻糖皮质激素对去卵巢兔皮质骨和松质骨的不良影响并改善股骨强度。
  • 结果提示阿巴洛帕肽作为糖皮质激素诱导骨质疏松的研究性疗法具有潜在前景。

研究设计与样本

  • 32只兔行去卵巢手术,8只行假手术。
  • 术后1天起24只去卵巢兔每日皮下注射甲泼尼龙1 mg/kg/日共6周,8只去卵巢兔和8只假手术对照不接受糖皮质激素。
  • 接受糖皮质激素的兔(每组8只)随后12周继续接受糖皮质激素(0.5 mg/kg/日)并每日皮下注射溶媒(GC-OVX组)、阿巴洛帕肽5 μg/kg/日(ABL5组)或25 μg/kg/日(ABL25组),未接受糖皮质激素的去卵巢和假手术对照每日注射溶媒。

主要发现

  • GC-OVX组椎体和股骨近端面积骨密度、股骨中段皮质面积、厚度和体积骨密度及椎体与股骨远端松质骨体积和体积骨密度均显著低于假手术对照。
  • ABL25组上述缺陷显著逆转,且松质骨微结构较GC-OVX对照改善。
  • 破坏性弯曲试验显示GC-OVX组股骨中段极限载荷和弯曲刚度显著低于假手术对照,而ABL25组这些参数与假手术对照相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Glucorticoid (GC) therapy is the commonest cause of secondary osteoporosis. Ovariectomized rabbits receiving the GC methylprednisolone for 6 weeks exhibited relatively lower vertebral and femoral bone mass. Treatment with the PTH receptor agonist abaloparatide for 12 weeks during ongoing methylprednisolone administration increased cortical and trabecular bone mass and femur bending strength. INTRODUCTION: Abaloparatide, an osteoanabolic PTHrP analog, increases bone mineral density (BMD) and reduces fracture risk in women with postmenopausal osteoporosis. This study assessed abaloparatide effects on BMD and bone strength in ovariectomized (OVX) rabbits with glucocorticoid (GC)-induced osteopenia. METHODS: Thirty-two rabbits underwent OVX and 8 underwent sham surgery. One day later, 24 OVX rabbits began daily s.c. GC injections (methylprednisolone, 1 mg/kg/day) for 6 weeks, while 8 OVX and 8 sham controls received no GC. GC-challenged rabbits (8/group) then received GC (0.5 mg/kg/day) along with daily s.c. vehicle (GC-OVX), abaloparatide 5 μg/kg/day (ABL5), or 25 μg/kg/day (ABL25) for 12 weeks, and the no-GC OVX and sham controls received daily vehicle. RESULTS: GC-OVX rabbits showed significant deficits in vertebral and proximal femur areal BMD, lower cortical area, thickness and volumetric BMD of the femur diaphysis, and reduced trabecular bone volume and volumetric BMD in the vertebra and distal femur versus sham controls. These deficits were significantly reversed in the ABL25 group, which also showed enhanced trabecular micro-architecture versus GC-OVX controls. Destructive bending tests showed significantly lower femur diaphysis ultimate load and bending rigidity of the femoral diaphysis in the GC-OVX group versus sham controls, whereas these parameters were similar in the ABL25 group vs sham controls. CONCLUSIONS: Abaloparatide 25 μg/kg/day mitigated the adverse effects of GC administration on cortical and trabecular bone and improved femoral strength in OVX rabbits. These results suggest potential promise for abaloparatide as an investigational therapy for glucocorticoid-induced osteoporosis.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Chandler H, Brooks DJ, Hattersley G, et al. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia. Osteoporos Int. 2019. PMID: 31053927. doi:10.1007/s00198-019-04999-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。